Newron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the FDA agreed a plan to address potential safety issues emerging from
Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
